Comparison of aspirin and indobufen in healthy volunteers

Platelets

Volumn 27, Issue 2, 2016, Pages 105-109

  Lee, Jong Young ^a   Sung, Ki Chul ^a   Choi, Hyo In ^b  

^a Sungkyunkwan University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Aspirin; indobufen; platelet

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; INDOBUFEN; PROSTAGLANDIN SYNTHASE; THROMBOXANE; ANTITHROMBOCYTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; ISOINDOLE DERIVATIVE; THROMBOXANE B2;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RASH; THROMBOCYTE AGGREGATION; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; AGED; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; PHENYLBUTYRATES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANE B2;

EID: 84959106847     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2015.1042853     Document Type: Article

References (14)

1. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405-410
2. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-e575S
3. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107: 1796-1801
4. Raju N, Sobieraj-Teague M, Hirsh J, ODonnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011; 124: 621-629
5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
6. De Caterina R, Sicari R, Yan A, Bernini W, Giannessi D, Lazzerini G, Efthymiopoulos C, Strolin-Benedetti M. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man. Thromb Haemost 1992; 67: 258-263
7. De Caterina R, Giannessi D, Bernini W, Lazzerini G, Lavezzari M, Stragliotto E, Biagi G, Coccheri S. A prostacyclin-sparing effect of indobufen vs. aspirin. Thromb Haemost 1996; 75: 510-514
8. Fornaro G, Rossi P, Mantica PG, Caccia ME, Aralda D, Lavezzari M, Pamparana F, Milanesi G. Indobufen in the prevention of thromboembolic complications in patients with heart disease: A randomized, placebo-controlled, double-blind study. Circulation 1993; 87: 162-164
9. Bhana N, Mcclellan KJ. Indobufen: An updated review of its use in the management of atherothrombosis. Drugs Aging 2001; 18: 369-388
10. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, Cataldo G, Milanesi G, Lavezzari M, Pamparana F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation: SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997; 28: 1015-1021
11. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2751-2753
12. Pamukcu B, Oflaz H, Nisanci Y. A current problem in atherothrombotic diseases-aspirin resistance: Definition, mechanisms, determination with laboratory tests and clinical implications. Anadolu Kardiyol Derg 2007; 7: 20-26
13. Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M, Montorfano M, Colombo A. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. Int J Cardiol 2013; 165: 444-447
14. Barilla F, Pulcinelli FM, Mangieri E, Torromeo C, Tanzilli G, Dominici T, Pellicano M, Paravati V, Acconcia MC, Gaudio C. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. Platelets 2013; 24: 183-188